Madrigal Pharmaceuticals Inc - Company Profile

All the sales intelligence you need on Madrigal Pharmaceuticals Inc in one solution.

Save hours of research time with a comprehensive
Sales Intelligence Solution.
Understand how Madrigal Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
Gain competitive edge with triggers that tell you
when and how to engage with Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc: Segment Analysis

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Related keylists

Business Description

Madrigal Pharmaceuticals Inc (Madrigal) is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The company is engaged in research and development activities to address the high unmet medical need associated with MASH, which can lead to cirrhosis, liver failure, and premature mortality.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

R&D Overview

Madrigal's R&D arm focuses on building a leading pipeline in MASH treatment. The company is developing several mechanisms that complement resmetirom to enhance efficacy across the MASH spectrum. Key initiatives include the development of MGL-2086, an oral GLP-1 receptor agonist, and ervogastat, an oral DGAT-2 inhibitor. Additionally, the company is exploring siRNA programs targeting genes implicated in MASH disease progression. These efforts aim to advance innovative therapies and build a robust pipeline for future MASH care. Madrigal R&D activities are managed by clinical program managers who oversee clinical trials. The company contracts with clinical research organizations to manage trials under agreed budgets. The R&D unit is responsible for research activities, clinical development of product candidates, and managing manufacturing expenses related to drug formulation and production. The company’s R&D activities are managed by a team of 258 individuals engaged in research, development, and medical affairs. In FY2025, the company spent US$388.5 million on its R&D, which stood at 40.5% of company’s total revenue. As of December 31, 2025, the company owned or co-owned exclusive rights to nine US and 107 foreign issued; 24 US and 97 foreign pending patent applications; and three international patent application filed under the Patent Cooperation Treaty. The company has a major technology alliance with Roche, which includes an exclusive license to certain US and foreign patents and patent applications owned by Roche, as well as Roche know-how relating to resmetirom.

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Who We Are

Industries We Cover

Who We Serve

Corporates

Financial Institutions

Professional Services

Other

What We Offer

Intelligence Centers

Consultancy

Marketplace